be diagnosed with CMV disease coincident with or prior to having a positive CMV surveillance culture. 1,7-9 Prophylactic strategies result in administration of antiviral drugs We prospectively monitored 61 allogeneic BMT patients for evidence of CMV infection and disease starting 7 to 30-40% of patients who would not have CMV infection or disease.
Summary:
be diagnosed with CMV disease coincident with or prior to having a positive CMV surveillance culture. 1,7-9 Prophylactic strategies result in administration of antiviral drugs We prospectively monitored 61 allogeneic BMT patients for evidence of CMV infection and disease starting 7 to 30-40% of patients who would not have CMV infection or disease.
1,5
days prior to transplant until day 110 after transplant. Patients receiving pre-and post-transplantation ganTo employ effectively an early treatment strategy for CMV infection requires a diagnostic test which is rapid and ciclovir prophylaxis were followed for the incidence of infection by the CMV antigenemia assay and shell vial risk stratifies patients for subsequent disease. Previously, centrifugation cultures have been used as a marker of CMV cultures. The median age of all patients was 32 years (range 5-54 years). Fourteen (25%) of 57 evaluable replication to initiate antiviral therapy in MT patients but have lacked sensitivity. 1, 8 The CMV antigen assay appears patients became CMV antigenemia or culture positive. The incidence of culture or antigenemia positivity in to be more sensitive than viral culture 10- 13 and provides diagnostic results in a few hours as opposed to culture tech-CMV seropositive or seronegative patients with a seropositive donor was 29% (14 of 49 patients). The antiniques which may take a few days to weeks. 10,14, 15 The assay is based on the detection from the peripheral blood genemia assay became positive a median of 29 days (range 12-89 days) after BMT as compared to 46 days of patients to a CMV late matrix tegument protein pp65.
16,17
The assay depends on the use of a pool of monoclonal anti-(range 26-98 days) by shell vial assay (P Ͻ 0.001). There were no cases of CMV disease in the first 110 days after bodies directed against epitopes on this protein. In this study we investigated the use of the CMV antigen assay to transplant. This study demonstrates that despite the use of prophylactic ganciclovir, BMT patients developed monitor the development of CMV infection in allogeneic BMT patients receiving prophylactic ganciclovir for the CMV infection but did not progress to disease in this study, the CMV antigenemia assay may be used to prevention of CMV disease. The assay was compared with viral culture and the centrifugation assay for sensitivity monitor for CMV infection during prophylaxis, and the current regimens for CMV prophylaxis with ganciclovir and specificity. may require further evaluation to determine an optimal regimen to prevent CMV infection. Keywords: CMV; bone marrow transplant; antigenemia;
Patients and methods diagnosis; viremia Patients
The study group was comprised of 61 consecutive patients Cytomegalovirus (CMV) remains an important opportuundergoing allogeneic MT between December 1992 and nistic infection following allogeneic BMT.
1 Recently, September 1993 (Table 1) . Patients were followed from day effective strategies for the prevention of CMV disease have −7 to day 100 after transplant. Blood was obtained weekly been developed in which ganciclovir has been given to for virus culture and the antigenemia assay. Urine cultures BMT patients either prophylactically (to all CMV seroposiwere collected weekly. Virus cultures were obtained from tive patients) terstained with FITC-conjugated goat anti-mouse IG F(ab) syndrome (Biotest, Denville, NJ, USA) diluted in PBS 1% human CLL 1 (7) 4 (9) albumin and 0.0005% Evans blue. Positive cells showed a Lymphoma 1 (7) 3 (7) yellow-green nuclear staining. Positive controls consisted
of infected fibroblast or leukocytes from patients known to ALL 1 (7) 6 (14) Donor be CMV antigenemia positive. 
Results

Pos/Pos
11 (78) 18 (42) Pos/Neg 1 (7) 8 (19) Sixty-one patients were enrolled in the study but four Neg/Pos 2 (14) 9 (21) Neg/Neg 0 (0) 8 (19) patients were excluded from the analysis. Two patients Graft-versus-host excreted CMV prior to the start of monitoring, one patient disease died during conditioning therapy, and one patient was lost 0-1 6 (43) 23 (53) to follow-up prior to obtaining blood for culture and anti-2-4 8 (57) 20 (46) genemia assays. Fifty-seven patients were evaluated for the final analysis (Table 1) . Eight patients who were CMV CML = chronic myelogenous leukemia; AML = acute myelogenous leukemia; CLL = chronic lymphocytic leukemia; ALL = acute lymphocytic leuseronegative with seronegative donors were included.
kemia.
Forty-three (75%) of the patients remained culture and antigen negative and represented the control group. There were no significant differences between the culture and antigen negative and culture and antigen positive groups, except for positive donor recipients pairs (P = 0.02). Fourteen (25%) of 57 patients (29% of 49 CMV seroweek. Beginning in October 1992, most patients received positive donor/patient combinations) became culture or the five times per week regimen unless the attending physantigenemia positive (Table 2 ). Eleven of the 14 patients ician directed differently. At day −1, patients were switched had a positive viral culture at some site (blood = 9, to acyclovir 500 mg/m 2 every 8 h until engraftment (ANC urine = 1, sputum = 1). Thirteen of the fourteen patients у1 × 10 9 /l for 2 consecutive days). Three patients received were positive for CMV antigenemia. Ten of the 13 patients ganciclovir 5 mg/kg three times per week (Table 2 ). All who were antigenemia positive had corresponding positive patients received intravenous immunoglobulin 500 mg/kg virus cultures. All patients who were culture positive were weekly from admission to day 110. Patients who became antigenemia positive. The exception was a patient who had CMV culture positive received ganciclovir treatment at a a positive sputum culture on day 45 after transplant who dose of 5 mg/kg twice per day or foscarnet 60 mg/kg three remained antigenemia negative. The median time to CMV times per day. The decision to use foscarnet was made by antigenemia or culture positivity was 29 days (range 12-the attending physician and was based on ganciclovir toxi-89 days) and 46 days (range 26-98 days), respectively (P city (neutropenia or thrombocytopenia). The treatment dur-Ͻ 0.0001, paired log rank test) (Figure 1 ). All nine patients ation was determined by the clinical judgement of the who were blood culture positive were antigenemia positive. attending physician. Patients who were CMV seronegative A positive antigenemia test preceded all positive blood and received a marrow from a CMV seronegative donor shell vial cultures by a median of 14 days. One patient who received CMV seronegative blood products.
was antigenemia positive on day 89 after transplant had a positive urine culture on day 98 after transplant but remained blood culture negative.
Statistical evaluation
Three patients were antigenemia positive on days 12, 26 and 29 after transplant without having a positive CMV culThe statistical analysis was performed using the 2 test and a two-tailed Fisher exact test as appropriate for examination ture from any site. Two of the three patients were on inadequate anti-CMV prophylaxis (acyclovir and ganciclovir of differences in proportions, and the Mann-Whitney test for evaluation of differences between medians. Time-tothree times per week) when they became antigenemia positive. Both patients became antigenemia negative upon event variables were estimated according to the method of Kaplan and Meier 18 and compared using paired and the institution of ganciclovir five times per week. One patient did develop antigenemia on ganciclovir prophylaxis unpaired log rank test, as appropriate. specificity of antigenemia could not be determined for CMV disease. However, the sensitivity and specificity could be determined for a positive CMV culture. The sensitivity of antigenemia for a positive viral culture at any site was 90% with a specificity of 93%. The positive and negative predictive values were 77% and 98% respectively. Since viremia may be predictive for subsequent CMV disease, an analysis was done with only patients who were viremic. The sensitivity and specificity of CMV antigenemia for predicting subsequent viremia was 100% and 91% respectively. The positive and negative predictive values were 69% and 100% respectively.
Outcome of antigenemia positive patients
CMV antigenemia was detected in four patients at 12, 14, 16 and 21 days post-transplant while still on acyclovir. One antigenemia and were treated with therapeutic doses of ganciclovir (5 mg/kg twice per day).
CMV antigenemia was detected in eight patients on ganfive times per week and subsequently became negative after ganciclovir was discontinued for seizures. None of the eight ciclovir or foscarnet prophylaxis. Two patients remained culture negative. One of these became antigenemia negative patients who were CMV seronegative with seronegative donors became CMV culture positive or antigenemia after 14 days even though the ganciclovir was discontinued when the patient had a seizure. The other became antigenpositive.
emia negative when the ganciclovir prophylaxis was increased from three times per week to five times per week; Sensitivity and specificity interestingly, antigenemia recurred 1 month later in this patient and resolved without any further changes in therapy. None of the patients in this study were diagnosed with CMV disease despite being viremic. The sensitivity and
Six patients who were CMV antigenemia-positive sub-sequently developed positive cultures for CMV and were while receiving acyclovir, was switched to ganciclovir and became antigenemia negative. Other studies in BMT, liver, treated. The CMV antigen positive patients were on prophylactic ganciclovir a median of 5 days (range 1-12 kidney, and heart transplants have mentioned a dissociation between cultures and antigenemia similar to what was days) before becoming antigen positive.
Two antigenemia-positive and 17 antigenemia-negative found in our study. 11, 12, 23, 25 Whether this dissociation reflects an increased sensitivity of antigenemia for CMV patients died in the study prior to day 110 (log rank test, P = 0.18). The primary causes of death were regimen replication or false positivity remains to be determined. Finally, none of the patients in this study infected with related toxicity (n = 1), relapse of underlying disease (n = 6), disseminated aspergillus (n = 4), Candida krusei CMV progressed to CMV disease. This raises the question about the need to monitor patients during antiviral prophysepsis (n = 3), Torulopis glabrata sepsis (n = 2), RSV pneumonia (n = 2), and liver failure (n = 1). No deaths were laxis. In this study, we did not monitor for emergence of ganciclovir resistance. Ganciclovir resistance has been attributable to CMV disease. described in immunocompromised hosts receiving ganciclovir. [26] [27] [28] Persistent CMV infection due to antiviral resistance may be missed without a system of monitoring.
Discussion
In addition, our study is limited owing to the small number of patients who became infected. In a larger study of 216 In this study, we have detailed our initial experience with the CMV antigenemia assay in allogeneic BMT patients allogeneic marrow transplant patients, some patients who excreted CMV while on ganciclovir prophylaxis did proreceiving prophylactic antivirals. Rapid methods for the diagnosis of CMV have become clinically important since gress to CMV disease. These patients had risk factors suggesting a greater depth of immunosuppression as shown the advent of effective antivirals and the discovery and confirmation of the predictive value for CMV disease by the by their progression to CMV disease despite prophylactic therapy (J Goodrich and E Whimsey; personal recovery of CMV from the blood or bronchoalveolar fluid in allogeneic BMT patients. 7, 8, 19, 20 The current clinical stancommunication). These data suggest a need at least to monitor certain patients at high risk for progression to dard has been the centrifugation assay for rapid detection of CMV from a variety of sites. 21, 22 CMV disease.
In conclusion, the antigenemia assay was sensitive, with We have found the antigenemia assay to be a sensitive and specific assay for the detection of CMV in BMT a relatively high positive and negative predictive value. All patients who were viremic had a positive antigenemia test patients. The sensitivity of antigenemia for a positive culture at any site was 90% with a specificity of 93%. The a median of 14 days before a positive culture suggesting the test would be adequate for monitoring patients. The one patient who did not have a positive antigenemia test had a positive culture from an endotracheal aspirate but did question of false positive results remains to be resolved definitively. not die of CMV disease. Since all patients in this study received prophylactic antivirals, we were unable to answer the question of the sensitivity and specificity of antigenemia for CMV disease. Viremia has been shown to be a marker Acknowledgements for CMV disease in BMT patients. 8, 20 The positive predicWe wish to acknowledge the technical help of Sandhya Misra.
tive value of antigenemia for CMV viremia was 69% which is comparable to another study. 23 Additionally, all patients with viremia were positive by antigenemia an average of References 14 days prior to the first positive centrifugation culture providing the opportunity to institute antiviral therapy. In cases 
